forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Drugs Market Size to Hit USD 132.79 Bn by 2035 Two Years After Stopping GLP-1s,

Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes

DPP-4 inhibitors carry a minimal risk of hypoglycemia and gastrointestinal symptoms

Patients inject the medication in the abdomen, thigh, or upper arm and rotate injection sites with each dose

Analyst (conference Manager) | Innovations in Pharma R&D Tuesday Feature | Inspiring the Future of Translational Medicine We are honored to welcome Daria Mochly-Rosen, Professor of Chemical and Systems Biology at Stanford University, as a Keynote Speaker at InnoPharm-2026, taking place November 24, 2026 at the Holiday Inn Boston Hotel